Articles from Azurity Pharmaceuticals

Ferabright is the first and only iron-based contrast agent for MRI in the brain

Woburn, MA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution will be available mid-2026 for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.

First and Only FDA-Approved, Ready-to-Use Clonidine Oral Solution for Hypertension Control in Adult Patients

This Strategic Transaction Expands Azurity’s Existing Gastrointestinal Portfolio

New York, NY and Woburn, MA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals names Ogilvy Health as public relations and marketing agency of record. Ogilvy Health's mandate will focus on reimagining Azurity's brand story centered on patient commitment and pioneering growth. The agency will also enhance Azurity's external visibility – both online and offline – and oversee the development of a new website to deliver dynamic content to all stakeholders, ensuring measurable impact across every channel.

First and Only FDA-Approved, Ready-to-Use Clonidine Oral Solution for Hypertension Control in Adult Patients

Woburn, MA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1